LSBCF (LakeShore Biopharma Co) Total Receivables: $69.22 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Total Receivables?

LakeShore Biopharma Co LSBCF Total Receivables is $69.22 Mil as of Mar. 2025. The stock has 5 warning signs investors should review.

LakeShore Biopharma Co's Total Receivables for the quarter that ended in Mar. 2025 was $69.22 Mil.

LakeShore Biopharma Co Total Receivables Related Terms

LakeShore Biopharma Co Total Receivables Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Total Receivables Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Total Receivables
38.11 48.63 67.95 62.09 69.22

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Total Receivables Get a 7-Day Free Trial Premium Member Only 67.95 58.84 62.09 74.83 69.22

LakeShore Biopharma Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $69.22 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Total Receivables of $69.22 Mil as of Mar. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Total Receivables too high?
LakeShore Biopharma Co's current Total Receivables is $69.22 Mil.
How does LakeShore Biopharma Co's Total Receivables compare to ACUT and PPCB?
LakeShore Biopharma Co's Total Receivables of $69.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Total Receivables is $69.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Total Receivables of $69.22 Mil. The current Total Receivables is $69.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Total Receivables is $69.22 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.